Nordic Nanovector is committed to building a pipeline of novel antibody radionuclide conjugates and antibody drug conjugates addressing multiple selected haematological malignancies based on proprietary technologies and expertise, and with technologies from partners where complementary. The company aspires to become a leader in the development of CD37-targeted therapies for haematological cancers and immune diseases, with Betalutin® representing a growing market forecast to be worth nearly USD 26 billion by 2028.